ArticleLeukemia2011
Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance.
Article in Leukemia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.Journal of hematopathology · 2026Article
- Article
- The Role of CTNNA1 in Malignancies: An Updated Review.Journal of Cancer · 2023Review
- Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance.Haematologica · 2021Article
- Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.Current hematologic malignancy reports · 2020Review
- Review
- Identify latent chromosomal aberrations relevant to myelodysplastic syndromes.Scientific reports · 2017Article
- TET2 mutation in diffuse large B-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2017Article
- Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Article
- The progress of early growth response factor 1 and leukemia.Intractable & rare diseases research · 2016Review
- Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.PloS one · 2016Article
- Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).International journal of medical sciences · 2015Article
- Microarray-based genomic profiling and in situ hybridization on fibrotic bone marrow biopsies for the identification of numerical chromosomal abnormalities in myelodysplastic syndrome.Molecular cytogenetics · 2015Article
- Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus.Arthritis research & therapy · 2014Article
- Clinical significance of previously cryptic copy number alterations and loss of heterozygosity in pediatric acute myeloid leukemia and myelodysplastic syndrome determined using combined array comparative genomic hybridization plus single-nucleotide polymorphism microarray analyses.Journal of Korean medical science · 2014Article
- Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results.Molecular cytogenetics · 2014Article
- There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Current hematologic malignancy reports · 2013Review
- Standardizing the initial evaluation for myelodysplastic syndromes.Current hematologic malignancy reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 40% of patients with myelodysplastic syndromes (MDSs) present with a normal karyotype, and they are facing different courses of disease. To advance the biological understanding and to find molecular prognostic markers, we performed a high-resolution oligonucleotide array study of 107 MDS patients (French American British) with a normal karyotype and clinical follow-up through the Duesseldorf MDS registry. Recurrent hidden deletions overlapping with known cytogenetic aberrations or sites of known tumor-associated genes were identified in 4q24 (TET2, 2x), 5q31.2 (2x), 7q22.1 (3x) and 21q22.12 (RUNX1, 2x). One patient with a 7q22.1 deletion had an additional 5q31.2 deletion of the acute myeloid leukemia/MDS region, the smallest deletion identified so far and including the putative tumor suppressor (ts) genes, EGR1 and CTNNA1. One TET2 deletion was homozygous and one heterozygous, with a missense mutation in the remaining allele, further supporting its role as a ts gene. Besides these recurrent alterations, additional individual imbalances were found in 34 cases; in total, 42/107 (39%) cases had genomic imbalances. These patients had an inferior survival as compared with the rest of the patients (P=0.002). This study emphasizes the heterogeneity of MDS, but points to interesting genes that may have diagnostic and prognostic impact.
Indexed as
Identifiers
21274003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.